# US 8,278,038 B2 · Methods for the identification, assessment, and treatment of patients with cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,038 B2
- Document ID: US8278038B2
- Status: Granted
- Kind: B2
- Application number: 11/449,195
- Filed: 2006-06-08
- Published: 2006-12-14
- Granted: 2012-10-02
- Earliest claimed: 2005-06-08
- Assignees: Millennium Pharmaceuticals, Inc.
- Inventors: Barbara M. Bryant; Andrew I. Damokosh; George Mulligan
- Web page: https://patentgrep.com/patent/US8278038B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/69: Boron compounds
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- G01N 33/57505: of the blood, e.g. leukaemia
- G01N 33/57515: of the breast
- G01N 33/5752: of the lungs
- G01N 33/57525: of the liver or pancreas
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- G01N 33/57545: of the ovaries
- G01N 33/57555: of the prostate
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G06Q 20/40: Authorisation, e.g. identification of payer or payee, verification of customer or shop credentials; Review and approval of payers, e.g. check credit lines or negative lists
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation
- G16B 40/10: Signal processing, e.g. from mass spectrometry [MS] or from PCR
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 20/40: relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- G01N 2800/44: Multiple drug resistance
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G06Q: INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

## Claims

### Claim 1

A method for determining a cancer therapy regimen for treating myeloma in a patient comprising:
a) measuring the level of expression of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 1-547 in Table 1A, 658-871 in Table 1B and 873-876 in Table 1B in a patient sample comprising tumor cells,
wherein the sequences recognized by probesets of the predictive markers:
i) numbered 1-547 consist of SEQ ID NOs: 1-513,
ii) numbered 658-871 and 873-876 consist of SEQ ID NOs:614-830;
b) comparing the level of expression of the at least one nucleic acid sequence to a reference expression level of that sequence to determine whether the level of expression of the at least one nucleic acid sequence is upregulated in the patient sample comprising tumor cells; and
c) determining a cancer therapy regimen for treating myeloma based on the expression level of the predictive marker or markers,
wherein the cancer therapy regimen is proteasome inhibition-based therapy, wherein
i) upregulation of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 1-547 indicates nonresponsiveness to proteasome inhibition therapy and the patient would not benefit from this cancer therapy regimen; and
ii) upregulation of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 658-871 and 873-876 indicates responsiveness to proteasome inhibition therapy and the patient would benefit from this cancer therapy regimen.

### Claim 2 (depends on 1)

The method of claim 1 wherein the level of expression of the at least one nucleic acid sequence is measured by detection of mRNA.

### Claim 3 (depends on 1)

The method of claim 1 wherein the expression level is measured for a predictive marker set comprising two or more predictive markers.

### Claim 4 (depends on 1)

The method of claim 1, wherein the proteasome inhibition-based regimen for treating the tumor comprises treatment with a proteasome inhibitor is selected from the group consisting of a peptidyl aldehyde, a peptidyl boronic acid, a peptidyl boronic ester, a vinyl sulfone, an epoxyketone, and a lactacystin analog.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient sample comprising tumor cells is obtained from the subject any time selected from prior to tumor therapy, concurrently with tumor therapy or after tumor therapy.

### Claim 6

A method for determining a cancer therapy regimen for treating myeloma in a patient comprising:
a) measuring the level of expression of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 658-871 and 873-876 in Table 1B in a patient sample comprising tumor cells,
wherein the sequences recognized by probesets of the predictive markers numbered 658-871 and 873-876 consist of SEQ ID NOs:614-830;
b) comparing the level of expression of the at least one nucleic acid sequence to a reference expression level of that sequence to determine whether the level of expression of the at least one nucleic acid sequence is upregulated; and
c) determining that the patient would benefit from peptide boronic acid therapy if there is upregulation of at least one nucleic acid sequence selected from the group consisting of sequences recognized by probesets of predictive markers numbered 658-871 and 873-876.

### Claim 7 (depends on 6)

The method of claim 6, wherein myeloma is multiple myeloma.

### Claim 8 (depends on 6)

The method of claim 6, wherein the patient sample comprising tumor cells is obtained from the subject any time selected from prior to tumor therapy, concurrently with tumor therapy or after tumor therapy.

### Claim 9 (depends on 6)

The method of claim 6, wherein the at least one nucleic acid sequence is sequences recognized by probesets of a predictive marker set which comprises at least 20 markers.

### Claim 10 (depends on 1)

The method of claim 1, wherein the at least one nucleic acid sequence is sequences recognized by probesets of a predictive marker set comprising a subset of markers identified in Table 4.

### Claim 11 (depends on 6)

The method of claim 6, wherein the peptide boronic acid therapy is bortezomib therapy.

### Claim 12 (depends on 10)

The method of claim 10, wherein the predictive marker set comprises at least 20 markers.

### Claim 13 (depends on 4)

The method of claim 4, wherein the proteasome inhibition-based regimen for treating the tumor comprises treatment with bortezomib.

### Claim 14 (depends on 5)

The method of claim 5, wherein the patient sample is obtained prior to therapy.
